paracetamolum/guaifenesinum/phenylephrini hydrochloridum richard bittner ag
richard bittner ag - paracetamolis/gvajfenezinas/fenilefrino hidrochloridas - kietosios kapsulės - 500 mg/100 mg/6,1 mg - paracetamol, combinations excl. psycholeptics
solpadeine
richard bittner ag - paracetamolis/kodeinas monohidratas/kofeinas - tabletės - 500 mg/8 mg/30 mg - paracetamol, combinations with psycholeptics
hotex
richard bittner ag - paracetamolis/gvajfenezinas/fenilefrino hidrochloridas - milteliai geriamajam tirpalui - 500 mg/200 mg/10 mg - paracetamol, combinations excl. psycholeptics
coldrex
richard bittner ag - paracetamolis/kofeinas/fenilefrino hidrochloridas/terpinhidratas/askorbo rūgštis - tabletės - 500 mg/25 mg/5 mg/20 mg/30 mg - paracetamol, combinations excl. psycholeptics
solpadeine express
richard bittner ag - paracetamolis/kofeinas - šnypščiosios tabletės - 500 mg/65 mg - paracetamol, combinations excl. psycholeptics
gelaspan
b.braun melsungen ag - Želatina/natrio chloridas/natrio acetatas trihidratas/kalio chloridas/kalcio chloridas dihidratas/magnio chloridas heksahidratas - infuzinis tirpalas - 40 g/5,55 g/3,27 g/0,3 g/0,15 g/0,2 g/1000 ml - gelatin agents
gelofusine
b.braun melsungen ag - Želatinos polisukcinatas/natrio chloridas/natrio hidroksidas - infuzinis tirpalas - 40 g/7,01 g/1,36 g/1000 ml - gelatin agents
resthizen
zenthique limited - klaritromicinas - milteliai infuzinio tirpalo koncentratui - 500 mg - clarithromycin
panadol extra
glaxosmithkline dungarvan limited - paracetamolis/kofeinas - plėvele dengtos tabletės - 500 mg/65 mg - paracetamol, combinations excl. psycholeptics
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - kiti nervų sistemos vaistai - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.